Novotech and Medidata expand partnership to continue advancements in clinical research

Leading Asia-Pacific biotech specialist CRO Novotech and Medidata renew partnership,further expanding services to Novotech clients in APAC and the US

SINGAPORE,June 16,2022 -- Medidata,a Dassault Systèmes company,today announced its renewed,expanded partnership with Novotech,a leading contract research organisation (CRO),to continue scaling clinical studies in various therapeutic areas from 2022.

Leveraging Rave EDC,Rave RTSM,eCOA and eConsent technology from Medidata,Novotech is equipped with flexible,configurable tools that can address clinical research needs at scale and facilitate accelerated drug and device development in Asia Pacific and the U.S.

Since its partnership in 2018,Novotech has doubled its growth and has also acquired CRO companies in APAC and the U.S. as well as invested in advanced DCT and data companies to deliver a seamless CRO platform amidst the increasing demand for clinical trials services in the region. The partnership extends access to a suite of end-to-end solutions from Medidata Clinical Cloud,the industry's only unified platform dedicated to clinical research. It also underscores Medidata and Novotech's commitment to work collaboratively towards accelerating clinical trials and research efficiently,while improving clinical trial timelines and patient experiences.

The Medidata Clinical Cloud is the only unified technology platform dedicated to clinical research,with solutions that leverage centralized data to address the holistic research process from start to finish. With the physical limitations and fragmentation of healthcare ecosystems caused by the COVID-19 pandemic,the need for digital integration for accelerated clinical development is crucial,and a unified platform allows for streamlined management of studies,sites,users,and access from a single location.

Edwin Ng,Senior Vice President,Asia Pacific,Medidata,commented,"The pandemic has underscored the importance of redesigning how trials are run,with more stakeholders realising the vital role that technology plays in clinical development. Medidata is pleased to continue our strong partnership with Novotech and is dedicated to providing support in their acceleration of clinical studies. Working with leading technologies,we can deliver better patient experiences and accelerate drug development in the new normal in clinical research."

Andries Claassen,Senior Director Biometrics,Novotech,added,"We are excited to continue our partnership with Medidata,with their sustained support in driving clinical research and business growth with customers. Novotech has always invested heavily in the latest technology to provide our clients with better data visibility for improved decision-making. Together,we will help sponsors deliver more efficient,effective,and scalable trials."

Medidata is a wholly owned subsidiary of Dassault Systèmes,which with its 3DEXPERIENCE platform is positioned to lead the digital transformation of life sciences in the age of personalized medicine with the first end-to-end scientific and business platform,from research to commercialization.

About Medidata

Medidata is leading the digital transformation of life sciences,creating hope for millions of patients. Medidata helps generate the evidence and insights to help pharmaceutical,biotech,medical device and diagnostics companies,and academic researchers accelerate value,minimize risk,and optimize outcomes. More than one million registered users across 2,000+ customers and partners access the world's most trusted platform for clinical development,commercial,and real-world data. Medidata,a Dassault Systèmes company (Euronext Paris: FR0014003TT8,DSY.PA),is headquartered in New York City and has offices around the world to meet the needs of its customers. Discover more at www.medidata.com and follow us @Medidata.

About Dassault Systèmes

Dassault Systèmes,the 3DEXPERIENCE Company,is a catalyst for human progress. We provide business and people with collaborative 3D virtual environments to imagine sustainable innovations. By creating virtual twin experiences of the real world with our 3DEXPERIENCE platform and applications,our customers push the boundaries of innovation,learning and production to achieve a more sustainable world for patients,citizens,and consumers. Dassault Systèmes brings value to more than 300,000 customers of all sizes,in all industries,in more than 140 countries. For more information,visit www.3ds.com/.

3DEXPERIENCE,the Compass icon,the 3DS logo,CATIA,BIOVIA,GEOVIA,SOLIDWORKS,3DVIA,ENOVIA,NETVIBES,MEDIDATA,CENTRIC PLM,3DEXCITE,SIMULIA,DELMIA,and IFWE are commercial trademarks or registered trademarks of Dassault Systèmes,a French "société européenne" (Versailles Commercial Register # B 322 306 440),or its subsidiaries in the United States and/or other countries.

About Novotech

Novotech is the leading Asia Pacific biotech specialist CRO with labs,phase I facilities,and drug development consulting services. Novotech has accumulated experience in over 3,700 clinical projects,including Phase I to Phase IV clinical trials and bioequivalence studies. Novotech is positioned to serve biopharmaceutical clients conducting clinical trials in Asia and globally and serves biotechs globally leveraging deep relationships built with hundreds of Asia-Pacific sites over the last 25 years. As of May 2022,Novotech has over 2,500 FTEs working across our offices in 12 geographies in Asia-Pacific and the United States.

For more information,please contact:

Paul Oestreicher

External Communications Director

Tel: +1-917-522-4692

Paul.Oestreicher@3ds.com